A combinational therapy of osimertinib with itraconazole (ITR) (NCT02157883) has also been suggested for NSCLC to overcome EGFR-TKI resistance (Vishwanathan et al., 2018). This evidence concerns the gene EGFR and non-small cell lung carcinoma.